What is HC Wainwright’s Forecast for GLSI FY2026 Earnings?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Equities researchers at HC Wainwright lowered their FY2026 earnings estimates for shares of Greenwich LifeSciences in a research note issued to investors on Tuesday, April 21st. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($1.22) for the year, down from their previous forecast of ($1.21). HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.23) per share.

Several other research firms have also weighed in on GLSI. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $47.50.

Greenwich LifeSciences Price Performance

Shares of NASDAQ:GLSI opened at $23.67 on Thursday. The company has a market capitalization of $327.83 million, a PE ratio of -16.21 and a beta of 1.53. Greenwich LifeSciences has a 1 year low of $7.78 and a 1 year high of $34.10. The business has a fifty day moving average price of $25.36 and a two-hundred day moving average price of $19.10.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GLSI. Bank of America Corp DE raised its stake in Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after acquiring an additional 1,322 shares during the period. Rhumbline Advisers boosted its position in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after purchasing an additional 3,168 shares during the period. Wells Fargo & Company MN increased its stake in shares of Greenwich LifeSciences by 109.6% in the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after purchasing an additional 4,102 shares in the last quarter. Strs Ohio bought a new stake in shares of Greenwich LifeSciences in the first quarter valued at approximately $177,000. Finally, Jane Street Group LLC bought a new stake in shares of Greenwich LifeSciences in the fourth quarter valued at approximately $203,000. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.